Article
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.
BMC cancer - 16 Dec 2015
Seibold Petra, Schmezer Peter, Behrens Sabine, Michailidou Kyriaki, Bolla Manjeet K, Wang Qin, Flesch-Janys Dieter, Nevanlinna Heli, Fagerholm Rainer, Aittomäki Kristiina, Blomqvist Carl, Margolin Sara, Mannermaa Arto, Kataja Vesa, Kosma Veli-Matti, Hartikainen Jaana M, Lambrechts Diether, Wildiers Hans, Kristensen Vessela, Alnæs Grethe Grenaker, Nord Silje, Borresen-Dale Anne-Lise, Hooning Maartje J, Hollestelle Antoinette, Jager Agnes, Seynaeve Caroline, Li Jingmei, Liu Jianjun, Humphreys Keith, Dunning Alison M, Rhenius Valerie, Shah Mitul, Kabisch Maria, Torres Diana, Ulmer Hans-Ulrich, Hamann Ute, Schildkraut Joellen M, Purrington Kristen S, Couch Fergus J, Hall Per, Pharoah Paul, Easton Doug F, Schmidt Marjanka K, Chang-Claude Jenny, Popanda Odilia
Abstract excerpt
BACKGROUND: Personalized therapy considering clinical and genetic patient characteristics will further improve breast cancer survival. Two widely used treatments, chemotherapy and radiotherapy, can induce oxidative DNA damage and, if not repaired, cell death. Since base excision repair (BER) activity is specific for oxidative DNA damage, we hypothesized that germline genetic variation in this pathway will affect...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.